Kathleen M. Nicholls

Grattan St
Parkville, VIC, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 46 publications

Scaling up Genomics: A Mainstream Model of Care in Nephrology.

Scaling up Genomics: A Mainstream Model of Care in Nephrology.

Journal: Clinical journal of the American Society of Nephrology : CJASN

Published: March 20, 2026

Sustained remission with eculizumab in refractory lupus nephritis with atypical haemolytic uraemic syndrome.

Sustained remission with eculizumab in refractory lupus nephritis with atypical haemolytic uraemic syndrome.

Journal: BMJ case reports

Published: October 31, 2025

Genetic Kidney Disease Across the Lifespan - Emerging Insights From Clinical Genomics in Older People.

Genetic Kidney Disease Across the Lifespan - Emerging Insights From Clinical Genomics in Older People.

Journal: Kidney international reports

Published: August 15, 2025

Long-term effectiveness and safety outcomes in adults with Fabry disease treated with agalsidase alfa: 20 years of data from the Fabry Outcome Survey.

Long-term effectiveness and safety outcomes in adults with Fabry disease treated with agalsidase alfa: 20 years of data from the Fabry Outcome Survey.

Journal: European journal of clinical investigation

Published: June 26, 2025

Two decades of experience of the Fabry Outcome Survey provides further confirmation of the long-term effectiveness of agalsidase alfa enzyme replacement therapy.

Two decades of experience of the Fabry Outcome Survey provides further confirmation of the long-term effectiveness of agalsidase alfa enzyme replacement therapy.

Journal: Molecular genetics and metabolism reports

Published: January 22, 2025

Troponin rise in Fabry disease: an Australian perspective.

Troponin rise in Fabry disease: an Australian perspective.

Journal: Internal medicine journal

Published: January 17, 2025

Sodium-glucose cotransporter 2 inhibitors reduce albuminuria in patients with Fabry disease: a real-world case series.

Sodium-glucose cotransporter 2 inhibitors reduce albuminuria in patients with Fabry disease: a real-world case series.

Journal: Internal medicine journal

Published: November 05, 2024

Lucerastat, an oral therapy for Fabry disease: results from a pivotal randomized phase 3 study and its open-label extension.

Lucerastat, an oral therapy for Fabry disease: results from a pivotal randomized phase 3 study and its open-label extension.

Journal: Nature communications

Published: July 24, 2024

Fabry Disease Podocytes Reveal Ferroptosis as a Potential Regulator of Cell Pathology.

Fabry Disease Podocytes Reveal Ferroptosis as a Potential Regulator of Cell Pathology.

Journal: Kidney international reports

Published: July 17, 2024

Enzyme replacement therapy in Fabry cardiomyopathy: an incomplete treatment.

Enzyme replacement therapy in Fabry cardiomyopathy: an incomplete treatment.

Journal: Heart (British Cardiac Society)

Published: June 21, 2024

The Effect of Fabry Disease Therapy on Bone Mineral Density.

The Effect of Fabry Disease Therapy on Bone Mineral Density.

Journal: Diseases (Basel, Switzerland)

Published: March 02, 2024

Fabry-specific treatment in Australia: time to align eligibility criteria with international best practices.

Fabry-specific treatment in Australia: time to align eligibility criteria with international best practices.

Journal: Internal medicine journal

Published: August 25, 2023

Showing 1-12 of 46

Last Updated: 09/26/2026